Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 for Agitation in Alzheimer's Dementia (TRIAD-1)
NCT02442765Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2015
- Primary completion
- Jan 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of dextromethorphan + quinidine in Alzheimer's disease (AD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jul 2015; status: completed.
02
Drugs
dextromethorphan + quinidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02442765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442765.